Exagen Inc.
NASDAQ:XGNMedical - Diagnostics & Research
+$0.16 today
- Market cap
- $99.50M
- Beta
- 2.02
- P/E (TTM)
- -5.2
- EPS (TTM)
- -$0.85
Volume 0.47M
Average 0.39M
XGN Total Non-current Assets
All assets not expected to be converted to cash within one year.
Exagen Inc.NASDAQ: XGN
Total Non-current Assets · Q1 FY2026 · quarter ended Mar 2026
Total non-current assets rises 7.5% from a year ago
Total non-current assets stood at $8.37M at the end of Q1 FY2026, up 7.5% from a year earlier and down 8.3% from the prior quarter. Over 3 fiscal years it compounded at -12.5% a year.
Context
- Total non-current assets amounted to 16.1% of total assets at the end of Q1 FY2026, down 3.2 pp from a year earlier.
- Total non-current assets increased in 1 of the last 3 fiscal years.
What to watch
Whether total non-current assets keeps rising in the next quarterly balance sheet after a +7.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Assets history
USD · from the balance sheet
- Latest · FY2025
- 9.13M USD
- Year-over-year change
- +10.9%
- 4-year CAGR
- -3.9%
| Period | Period end | Total Non-current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 9.13M | +10.9% |
| FY2024 | 2024-12-31 | 8.23M | -9.5% |
| FY2023 | 2023-12-31 | 9.1M | -33.1% |
| FY2022 | 2022-12-31 | 13.61M | +27.1% |
| FY2021 | 2021-12-31 | 10.71M | — |
Total Non-current Assets vs competitors
How XGN compares with its peers on the latest reported figures
- XGN's Mar 2026 total non-current assets of $8.37M is the 9th highest of the 11 companies compared; the peer median is $77.74M.
- Its year-over-year change of +7.5% is the 2nd highest of 10, against a peer median of -8.0%.
- Total non-current assets amounts to 16.1% of total assets for XGN, versus a peer median of 49.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $970.77M | -3.1% | -4.7% | 71.8% | |
| Dec 2025 | $149.89M | — | — | 64.6% | |
| Mar 2026 | $140.36M | -37.3% | +7.2% | 32.4% | |
| Jun 2026 | $89.06M | +2.5% | +1.7% | 67.4% | |
| Mar 2026 | $88.49M | -0.9% | -26.6% | 44.5% | |
| Mar 2026 | $66.98M | -9.8% | -8.8% | 67.9% | |
| Mar 2026 | $38.08M | -36.0% | -0.8% | 55.0% | |
| Mar 2026 | $18.2M | -8.0% | +21.9% | 33.7% | |
| Mar 2026 | $8.37M | +7.5% | -12.5% | 16.1% | |
BIOABioAge Labs, Inc. | Mar 2026 | $5.79M | -69.6% | +172.8% | 1.5% |
| Mar 2026 | $3.19M | +15.0% | -8.9% | 2.9% | |
| Peer median (excluding XGN) | $77.74M | -8.0% | -0.8% | 49.7% | |
Competitors are the stored peer set for XGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 99.44M | 62.39M | 36.49M | 22.04M | 32.22M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 9.65M | 6.08M | 6.55M | 7.84M | 10.86M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 490K | 236K | 1.93M | 859K | 38K |
| Total Current Assets | 112.73M | 72.61M | 47.84M | 36.46M | 48.89M |
| Property, Plant & Equipment (Net) | 4.77M | 13.08M | 8.49M | 7.68M | 8.37M |
| Goodwill | 5.51M | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 200K |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 433K | 528K | 616K | 550K | 556K |
| Total Non-current Assets | 10.71M | 13.61M | 9.1M | 8.23M | 9.13M |
| Total Assets | 123.45M | 86.22M | 56.94M | 44.69M | 58.02M |
| Account Payables | 2.49M | 3.05M | 3.13M | 4.14M | 4.15M |
| Short-term Debt | 587K | 190K | 264K | 423K | 3M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 675K |
| Other Current Liabilities | 2.19M | 445K | 0 | 0 | 6.33M |
| Total Current Liabilities | 9.32M | 9.62M | 11.9M | 13.51M | 14.16M |
| Long-term Debt | 27.48M | 28.78M | 19.23M | 19.82M | 22.26M |
| Deferred Tax Liabilities | 306K | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 1.41M | 867K | 357K | 157K | 3.71M |
| Total Non-current Liabilities | 29.19M | 34.14M | 22.35M | 21.64M | 26.41M |
| Total Liabilities | 38.51M | 43.76M | 34.25M | 35.15M | 40.57M |
| Common Stock | 16K | 17K | 17K | 18K | 23K |
| Retained Earnings | (208.14M) | (255.53M) | (279.22M) | (294.33M) | (314.28M) |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 84.94M | 42.46M | 22.69M | 9.54M | 17.45M |
| Total Debt | 28.07M | 35.2M | 23.23M | 23.01M | 25.71M |
| Net Debt | (71.38M) | (27.19M) | (13.26M) | 969K | (6.51M) |
Exagen Inc.
NASDAQ:XGN
Intrinsic Alpha fair value
Locked
Current Price
$3.90
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.